Hrsa-Ila Funds v. Adidas Ag

CourtCourt of Appeals for the Ninth Circuit
DecidedDecember 3, 2025
Docket24-6655
StatusUnpublished

This text of Hrsa-Ila Funds v. Adidas Ag (Hrsa-Ila Funds v. Adidas Ag) is published on Counsel Stack Legal Research, covering Court of Appeals for the Ninth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Hrsa-Ila Funds v. Adidas Ag, (9th Cir. 2025).

Opinion

NOT FOR PUBLICATION FILED UNITED STATES COURT OF APPEALS DEC 3 2025 MOLLY C. DWYER, CLERK U.S. COURT OF APPEALS FOR THE NINTH CIRCUIT

HRSA-ILA FUNDS, Individually and on No. 24-6655 behalf of all others similarly situated, D.C. No. 3:24-cv-00629-IM Plaintiff - Appellant,

v. MEMORANDUM*

ADIDAS AG and HARM OHLMEYER,

Defendants - Appellees,

and

KASPER RORSTED,

Defendant.

Appeal from the United States District Court for the District of Oregon Karin Immergut, District Judge, Presiding

Argued and Submitted October 23, 2025 San Francisco, California

Before: MURGUIA, Chief Judge, and OWENS and BUMATAY, Circuit Judges.

Plaintiff-Appellant HRSA-ILA Funds (“HRSA-ILA”) appeals the district

* This disposition is not appropriate for publication and is not precedent except as provided by Ninth Circuit Rule 36-3. court’s dismissal of its securities fraud claims against Defendant-Appellees adidas

AG (“Adidas”) and Harm Ohlmeyer (“Ohlmeyer”). HRSA-ILA, an Adidas

shareholder, brought a class action lawsuit asserting two claims: (1) violation of

section 10(b) of the Securities Exchange Act of 1934 (“Exchange Act”) and (2)

violation of section 20(a) of the Exchange Act.

HRSA-ILA alleges that Adidas had engaged in a significant partnership

(“Partnership”) with celebrity Ye (formerly known as Kanye West) and his shoe

company Yeezy, but later terminated the Partnership in Fall 2022 due to public

fallout from Ye’s antisemitic and other improper behavior. The fallout and

dissolution of the Partnership led to a decrease in Adidas’s share price. HRSA-ILA

claims that Adidas had known about and internally grappled with Ye’s antisemitic

and other improper behavior for years, yet misled shareholders by failing to disclose

this risk in its disclosures.

On appeal, HRSA-ILA argues that it adequately alleged actionable securities

fraud claims under section 10(b) for the two disclosures in dispute: (1) Adidas’s

Business Partners Risk disclosures; and (2) Adidas’s statements that it complied with

the European Union’s (“EU”) Global Reporting Initiative (“GRI”), as part of the

EU’s Non-Financial Reporting Directive (“NFRD”). We have jurisdiction under 28

U.S.C. § 1291. We affirm.

2 24-6655 We review the district court’s order dismissing the complaint de novo.

Mudpie, Inc. v. Travelers Cas. Ins. Co. of Am., 15 F.4th 885, 889 (9th Cir. 2021). In

a securities fraud case alleging section 10(b) claims, the complaint must meet the

heightened pleading standards of both Federal Rule of Civil Procedure (“FRCP”)

9(b) and the Private Securities Litigation Reform Act of 1995 (“PSLRA”). Zucco

Partners, LLC v. Digimarc Corp., 552 F.3d 981, 990 (9th Cir. 2009). FRCP 9(b)

requires a party alleging fraud to “state with particularity the circumstances

constituting fraud.” Fed. R. Civ. P. 9(b). The PSLRA requires the complaint to

“specify each statement alleged to have been misleading [and] the reason or reasons

why the statement is misleading.” 15 U.S.C. § 78u-4(b)(1)(B).

1. We affirm the district court’s conclusion that Plaintiff fails to plead an

actionable securities fraud claim for Adidas’s Business Partners Risk disclosures.1

To plead a successful section 10(b) claim, a plaintiff must adequately allege: “(1) a

material misrepresentation or omission by the defendant; (2) scienter; (3) a

connection between the misrepresentation or omission and the purchase or sale of a

security; (4) reliance upon the misrepresentation or omission; (5) economic loss; and

(6) loss causation.” Stoneridge Inv. Partners, LLC v. Scientific-Atlanta, 552 U.S.

1 The Business Partners Risk disclosure appeared in multiple annual reports, so it is sometimes referred to in plural form.

3 24-6655 148, 157 (2008). The district court determined that HRSA-ILA failed to allege an

actionable material misrepresentation or omission. We agree.

An actionable material misrepresentation or omission requires two

components. First, a plaintiff must “allege a misrepresentation or a misleading

omission with particularity and explain why it is misleading.” Retail Wholesale &

Dep’t Store Union Loc. 338 Ret. Fund v. Hewlett-Packard Co. (Hewlett-Packard),

845 F.3d 1268, 1274 (9th Cir. 2017). “Second, applying an objective standard, that

misrepresentation or omission must have been material to investors.” Id. Courts

apply the objective standard of a “reasonable” investor to determine whether a

statement is misleading. In re Alphabet, Inc. Sec. Litig. (Alphabet), 1 F.4th 687, 699

(9th Cir. 2021). And importantly, section 10(b) “do[es] not create an affirmative

duty to disclose any and all material information,” unless such disclosure is

necessary to ensure that the statements are not misleading. Matrixx Initiatives, Inc.

v. Siracusano, 563 U.S. 27, 44 (2011).

HRSA-ILA argues that Adidas misled shareholders through its Business

Partner Risk disclosure, which stated that:

Unethical business practices on the part of business partners or improper behavior of individual athletes, influencers or partners in the entertainment industry could have a negative spill-over effect on the company’s reputation, lead to higher costs or liabilities or even disrupt business activities.

4 24-6655 HRSA-ILA contends that the Business Partners Risk disclosure is misleading

because it treats the risk of improper behavior as hypothetical even though Adidas

knew that the warned-of risk had already come to pass through Ye’s antisemitic and

improper behavior. We disagree because the disclosure presents the hypothetical

risk as the negative effect of improper behavior, not the improper behavior itself.

We reject HRSA-ILA’s arguments that the Business Partners Risk disclosure

is analogous to the disclosures found misleading in Alphabet, 1 F.4th 687, and In re

Facebook, Inc. Sec. Litig. (Facebook), 87 F.4th 934 (9th Cir. 2023), because

Alphabet and Facebook dealt with historical data breaches that the companies

concealed, while this case involves a celebrity partner who already had public

notoriety for his improper behavior even prior to the Partnership. Cf. Alphabet, 1

F.4th at 704–05; Facebook, 87 F.4th at 949–50. Therefore, we conclude that a

reasonable investor would know that a partnership with a celebrity partner like Ye

would come with inherent risks relating to improper behavior and that a reasonable

investor would not be misled by the Business Partners Risk disclosures. See

Hewlett-Packard, 845 F.3d at 1274 (describing a statement as materially misleading

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
Hrsa-Ila Funds v. Adidas Ag, Counsel Stack Legal Research, https://law.counselstack.com/opinion/hrsa-ila-funds-v-adidas-ag-ca9-2025.